THUNDERCOMM
15.3.2023 04:57:35 CET | Business Wire | Press release
Thundercomm, a world leading IoT product and solution provider, announces the release of new offerings in its smart IoT module portfolio to lower the barriers to enter the market and accelerate innovation in various AIoT industry segments, including robotics, handheld devices, tablets and smart cameras.
TurboX C2210 SOM is powered by the Qualcomm® QRB2210 System-on-Chip (SoC). It's designed with an optimized Linux operating system, discrete memory for more memory options to save the cost, and system fast boot, supports 1080P@30FPS video decode and a long life cycle to 2028, aiming to bring advanced features to entry-level devices with better performance and improved power consumption. The TurboX C2210 SOM supports the Linux system and can be applied to a variety of products like entry-tier robotics, e-scooter, smart home dock, smart camera and rugged handheld, etc.
TurboX C4210 SOM is powered by the Qualcomm® QRB4210 SoC. It features triple ISPs for advanced dual-camera experience, dedicated Compute DSP for computer vision and video post-processing. It's designed to support advanced graphics, bringing high value features to mid-tier devices. It's an ideal platform for both industrial and consumer applications requiring high data rates multimedia function, and can be applied to a broad range of devices including robotics, dash camera, video conference, smart retail, etc.
TurboX C5430 SOM integrates the Qualcomm® QCS5430 SoC, a 6nm processor with superior performance, power efficiency, premium connectivity, and 3.5 TOPS computing power. It supports 4K@30FPS video decode and 4K@30FPS video encode, Wi-Fi 6E, long range bluetooth, four MIPI CSIs, as well as a rich set of peripheral interfaces. The C5430 SOM is a high performance AIoT SOM for building handheld devices, industrial robots, service robots, Edge Box, providing customers with hardware interfaces and software SDK to validate functions and build the prototype quickly.
“Robotics industry is growing faster than ever as technology continuously advances in 5G, computing power and AI. Today, we see robots in almost every aspect of our lives, helping us do much more than we can do alone. Our newly released C2210 SOM and C4210 SOM will unlock the potential of more innovations in robotics, lowering the barriers for brands to enter and compete efficiently in this growing market,” said Pier Zhang, Director of Product Marketing at Thundercomm. “We are offering not only the hardware SOM and dev kits, but also the robot brain, software solutions to help customers build future-proof robot products faster and cost-effectively.”
“We congratulate Thundercomm on the launch of their industry leading SOMs. Recognizing the innovation of these new products, Qualcomm Technologies recently announced Qualcomm® Robotics RB1 and RB2 Development Kits are based on TurboX C2210 and C4210 respectively,” said Dev Singh, vice president, business development, and head of building, enterprise and industrial automation, Qualcomm Technologies, Inc. “Boosting a suite of complete robotics capabilities, including pre-integrated sensors from TDK, cameras, and AI SDKs, our development kits will enable developers to more easily prototype everyday robotics applications thus helping push the IoT ecosystem forward.”
The Qualcomm Robotics RB1 and RB2 Development Kit and SOMs of TurboX C2210, C4210, C5430 are available now for evaluation and testing.
About Thundercomm
Thundercomm, a joint venture between Thunder Software Technology Co., Ltd and Qualcomm (China) Holding Co. Ltd., a subsidiary of Qualcomm Technologies, Inc., was established to accelerate innovation in the Internet of Things and automotive industry, providing one-stop solutions powered by Qualcomm Technologies. Through its capabilities in operating systems including Android, Linux, and others, abroad software and on-device AI technology portfolio, and a global sales and support network, Thundercomm is a valuable and trusted partner to global customers aiming to build high-quality, next-generation products and shorten time-to-commercialization. Learn more at www.thundercomm.com
Qualcomm branded products are products of Qualcomm Technologies, Inc. and/or its subsidiaries. Qualcomm patented technologies are licensed by Qualcomm Incorporated.
Qualcomm is a trademark or registered trademark of Qualcomm Incorporated.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230314006083/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Brenus Pharma Presented New Preclinical and Early Clinical Data in Colorectal Cancer During AACR Immuno-Oncology Conference 202619.2.2026 08:50:00 CET | Press release
Brenus Pharma, a clinical-stage biotechnology company pioneering in vivo “off-the-shelf” immunotherapies, announced the selection of an abstract for a poster presentation at the American Association for Cancer Research Immuno-Oncology (AACRIO) annual conference (February 18-21, 2026), in Los Angeles. The poster showcases new preclinical data and early clinical insights from the company's lead candidate, STC-1010, supporting it as a promising therapeutic option for MSS, immune-cold colorectal cancer (CRC)—a major unmet clinical need. In a syngeneic CT26 model, murine STC-1010 significantly inhibits tumor growth and extends survival by 40%. New mechanistic datas reveal expansion of CD4⁺ and CD8⁺ T cells in draining lymph nodes alongside a significant humoral response compared to control, demonstrating coordinated cellular and humoral immune activation in vivo. Other findings show that dendritic cells efficiently capture STC-1010, leading to their activation as demonstrated by transcripto
ENHERTU® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer19.2.2026 08:30:00 CET | Press release
Based on DESTINY-Breast05 phase 3 trial results, which showed ENHERTU reduced the risk of invasive disease recurrence or death by 53% compared to T-DM1 If approved, Daiichi Sankyo and AstraZeneca’s ENHERTU has the potential to become a new standard of care in this early breast cancer setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU® (trastuzumab deruxtecan) as a monotherapy for adult patients with HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer who have residual invasive disease after neoadjuvant HER2 targeted treatment. ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committ
NHOA Energy Advances Delivery of the 51 MWh Broni Battery for Neoen in Italy19.2.2026 08:00:00 CET | Press release
The project confirms NHOA Energy’s long-term commitment to the Italian market NHOA Energy, global provider of utility-scale energy storage systems, is advancing the construction of the Broni Battery, a 10 MW/51 MWh project located in Broni (Pavia), Italy, executed for Neoen, one of the world’s leading independent producers of renewable energy. Civil works at the site are currently underway and advancing on schedule, with commissioning activities planned to start in late spring 2026. Once operational, the Broni Battery will provide essential flexibility services to the Italian electricity system, supporting grid stability and reliability as renewable energy penetration continues to increase. The project represents Neoen’s first battery storage asset in Italy and marks a strategic step in the company’s expansion, as it continues to grow its battery storage portfolio in key markets worldwide to support power system flexibility. The Broni Battery further strengthens NHOA Energy’s long-term
Compass Pathways Announces Pricing of $150 Million Public Offering19.2.2026 02:18:00 CET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the pricing of its public offering of 17,500,000 American Depositary Shares (“ADSs”) at a public offering price of $8.00 per ADS, each representing one ordinary share, and in lieu of ADSs, to certain institutional investors, pre-funded warrants to purchase up to 1,250,000 ADSs at a public offering price of $7.9999 per pre-funded warrant. In addition, Compass Pathways has granted the underwriters a 30-day option to purchase up to an additional 2,812,500 ADSs at the public offering price, less the underwriting discounts and commissions. All of the securities are to be sold by Compass Pathways. The offering is expected to close on or about February 20, 2026, subject to the satisfaction of customary closing conditions. The gross proceeds to Compass Pathways from the offering, before deducting underwriting discounts and commissions and other est
Andersen Consulting udvider sine kompetencer inden for ledelsesrekruttering med Lansdowne Executive Search18.2.2026 17:08:00 CET | Pressemeddelelse
Andersen Consulting styrker sin humancapital-praksis gennem en samarbejdsaftale med Lansdowne Executive Search, der er en Dublin-baseret virksomhed med speciale i lederrekruttering, midlertidige ledelser og bestyrelsesudnævnelser. Lansdowne Executive Search er en irisk-ejet virksomhed, der blev grundlagt i 2015, og som tilbyder C-level-ledelsesekruttering, deltidsledere og bestyrelsesplaceringer. Som en partnerdrevet boutique-virksomhed er Lansdowne kendt for, at seniorledelsen er tæt involveret i alle kundeprojekter. Virksomheden hjælper kunder med at navigere i komplekse ledelsesovergange og vækststrategier på tværs af en bred vifte af sektorer, herunder finans, byggeindustrien, nonprofit, landbrug, videregående uddannelse, den offentlige sektor samt teknologi, medier og telekommunikation. "God ledelse er afhænger af situationen, og det kræver forståelse af langt mere end blot et CV," sagde Tom Keane, der er partner hos Lansdowne Executive Search. "Samarbejdet med Andersen Consulting
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom